ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category
Klaus H. Metzeler(University Hospital Leipzig), Clara D. Bloomfield(North Shore University Hospital), Heiko Becker(University of Freiburg), Meir Wetzler, Michael D. Radmacher, Michael A. Caligiuri(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Maria R. Baer(University of Maryland, Baltimore), Jessica Kohlschmidt(The Ohio State University), Guido Marcucci(City of Hope), Jonathan E. Kolitz(Memorial Sloan Kettering Cancer Center), Thomas H. Carter(University of Iowa), Richard A. Larson(Urbana University), Andrew J. Carroll(University of Alabama at Birmingham), Joseph O. Moore(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Krzysztof Mrózek(The Ohio State University), Deedra Nicolet(The Ohio State University), Bayard L. Powell(Atrium Health Wake Forest Baptist), Susan P. Whitman(The Ohio State University Wexner Medical Center), Sebastian Schwind, Yue-Zhong Wu(University of Iowa), Kati Maharry(Peter MacCallum Cancer Centre)
Cited by 278
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
|Blood|2009|4.4k